Yasuhiro Matsumura

The Rogosin Institute — United States

Medicine · Health Sciences

62h-index28.9kcitations392works1.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Monoclonal and Polyclonal Antibodies Research(57), Nanoparticle-Based Drug Delivery(52), HER2/EGFR in Cancer Research(41), Colorectal Cancer Treatments and Studies(26), Cancer Treatment and Pharmacology(26)

Publications392 total

Efficient Conjugation of Chelating Agents to IgG and Accurate Colorimetric Determination of the Chelate-to-IgG Molar Ratio.
2026Open Access
Geranyl diphosphate synthase small subunit I (GPPS.SSU I) expression strongly correlates with the presence or absence of monoterpene emission from lily (Lilium spp.) flowers
Planta·2025· 2 cited
Protection Measures for Lightning Overvoltages in a Low-Voltage Dc Power Supply System
2025
Anti‐tissue factor antibody conjugated with monomethyl auristatin E or deruxtecan in pancreatic cancer models
Cancer Science·2024· 6 citedOpen Access
398P Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): Additional analysies from 45-month (mo) follow-up of CheckMate 648
Annals of Oncology·2024· 1 cited
Effect of Single Oral Coingestion of GABA and Malic Acid on Postprandial GLP‐1, Glucose, and Insulin Responses in Healthy Volunteers: A Randomized, Double‐Blind, Placebo‐Controlled, Crossover Study
Molecular Nutrition & Food Research·2024· 1 cited
Remembering Prof. Hiroshi Maeda
Drug Delivery System·2024Open Access
Possible functions of ecdysone signaling reiteratively used in the adult honey bee brain
Frontiers in Bee Science·2023· 5 citedOpen Access
Figure S6 from U3-1402, a Novel HER3-Targeting Antibody–Drug Conjugate, for the Treatment of Colorectal Cancer
2023Open Access
Figure S3 from U3-1402, a Novel HER3-Targeting Antibody–Drug Conjugate, for the Treatment of Colorectal Cancer
2023Open Access
Figure S5 from U3-1402, a Novel HER3-Targeting Antibody–Drug Conjugate, for the Treatment of Colorectal Cancer
2023Open Access
Figure S3 from U3-1402, a Novel HER3-Targeting Antibody–Drug Conjugate, for the Treatment of Colorectal Cancer
2023Open Access
Figure S1 from U3-1402, a Novel HER3-Targeting Antibody–Drug Conjugate, for the Treatment of Colorectal Cancer
2023Open Access
Figure S2 from U3-1402, a Novel HER3-Targeting Antibody–Drug Conjugate, for the Treatment of Colorectal Cancer
2023Open Access
Figure S5 from U3-1402, a Novel HER3-Targeting Antibody–Drug Conjugate, for the Treatment of Colorectal Cancer
2023Open Access
Figure S1 from U3-1402, a Novel HER3-Targeting Antibody–Drug Conjugate, for the Treatment of Colorectal Cancer
2023Open Access
Figure S4 from U3-1402, a Novel HER3-Targeting Antibody–Drug Conjugate, for the Treatment of Colorectal Cancer
2023Open Access
Figure S4 from U3-1402, a Novel HER3-Targeting Antibody–Drug Conjugate, for the Treatment of Colorectal Cancer
2023Open Access
Figure S2 from U3-1402, a Novel HER3-Targeting Antibody–Drug Conjugate, for the Treatment of Colorectal Cancer
2023Open Access
Figure S6 from U3-1402, a Novel HER3-Targeting Antibody–Drug Conjugate, for the Treatment of Colorectal Cancer
2023Open Access
page 1 of 20Next →

Frequent Co-authors

Kazunori Kataoka(11), Nobuhiro Nishiyama(8), Masahiro Yasunaga(8), Yoshikatsu Koga(7), Yasuhide Yamada(5), Yasuhiro Shimada(5), Kuniaki Shirao(5), Tetsuya Hamaguchi(5), Kei Muro(4), Hiroshi Maeda(3), Tsuyoshi Hamaguchi(3), Horacio Cabral(3), Takahito Negishi(3), Fumiaki Koizumi(3), Tadao Kakizoe(3), Ken Kato(3), Masami Kimura(3), Seiichiro Yamamoto(3), Shino Manabe(3), Shigeto Fukushima(2)